Fig 3. HER3 and NMIIA protein levels are increased upon inhibition of HER2 in HER2+ breast cancer cells.

BT474 and MDA-MB-453 cells were treated with vehicle or neratinib (200 nM) for 24 hours. Cells were lysed and products analyzed by 10% SDS-PAGE followed by probing immunoblots with antibodies for p-HER2, HER2, NMIIA, HER3 and α-tubulin.